TAMOXIFEN BREAST CANCER PREVENTION TRIAL RESUMPTION RECOMMENDED
TAMOXIFEN BREAST CANCER PREVENTION TRIAL RESUMPTION RECOMMENDED by the BCPT End Results and Safety Monitoring Committee, which met on May 4. At a May 11 hearing before the Senate Cancer Coalition chaired by Sens. Feinstein (D-Calif.) and Mack (R-Fla.), National Cancer Institute Community Oncology and Rehabilitation Branch Chief Leslie Ford, MD, testified that the committee recommendation to resume the study with modifications has been approved by the NCI Division of Cancer Prevention and Control's Board of Scientific Counselors.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth